RxDoctor Payments Data

Ronald Gabor, MD

Cardiovascular Disease · Boca Raton, FLNPI 1184611642

Payments from drug & device makers

$2,532in general payments, 2019–2025

Across 50 payments — averaging $50.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$544
  • Boston Scientific$459
  • Astellas Pharma US Inc$375
  • Novo Nordisk$176
  • Impulse Dynamics (USA) Inc.$170
  • Boehringer Ingelheim$144
  • plus $664 from 11 others

What the payments were for

  • Food & beverage$2,15785%
  • Education$37515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,532 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$298,911
Medicare patients
1,771
Services billed
3,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban348$432,389
VyndamaxTafamidis15$346,186
EntrestoSacubitril/Valsartan159$214,462
XareltoRivaroxaban127$155,819
FarxigaDapagliflozin Propanediol89$104,907
JardianceEmpagliflozin64$85,008
MultaqDronedarone Hcl21$40,323
OzempicSemaglutide31$40,234
MounjaroTirzepatide22$32,637
Repatha SureclickEvolocumab24$21,966
BrilintaTicagrelor13$10,025
Metoprolol Succinate573$7,787
Rosuvastatin Calcium688$6,242
Praluent PenAlirocumab12$5,674
Midodrine Hcl61$5,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$70$778,575363 claims
NovartisEntresto$130$214,462159 claims
Johnson & JohnsonXarelto$125$155,819127 claims
AstraZenecaFarxiga, Brilinta$52$114,932102 claims
Boehringer IngelheimJardiance$144$85,00864 claims
Novo NordiskOzempic$176$40,23431 claims
Lilly USA, LLCMounjaro$24$32,63722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →